|
시장보고서
상품코드
2008073
소아용 항생제 시장 : 감염증별, 투여 경로별, 유통 채널별, 지역별Pediatric Antibiotics Market, By Infection, By Route Of Administration, By Distribution Channel, By Geography |
||||||
소아용 항생제 시장은 2026년에 68억 달러로 추정되며, 2033년까지 92억 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 3.1%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 68억 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 3.10% | 예측 금액(2033년) | 92억 달러 |
항생제는 특정 종류의 세균 감염을 치료하거나 예방하는 데 사용됩니다. 항생제는 세균을 사멸시키거나 세균의 증식 및 확산을 막는 방식으로 효과를 발휘합니다. 항생제는 소아에서 가장 흔하게 처방되는 약물로, 비특이적 상기도 감염이나 요로 감염과 같은 심각한 세균 감염을 앓고 있는 환자의 생명을 구할 수 있는 잠재력을 가지고 있습니다. 항생제는 경구 투여되며 정제, 액상 현탁액, 캡슐 등의 형태로 제공됩니다. 또한, 항생제를 정맥으로 투여하기도 합니다. 외용제로는 연고, 크림, 로션 등의 형태로 사용할 수 있습니다.
시장 역학
세계 소아 항생제 시장에서 활동하는 주요 기업들은 제품 승인과 같은 성장 전략을 채택하는 데 주력하고 있으며, 이는 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2020년 1월, 미국 및 캐나다 이외 지역에서는 MSD로 알려진 세계적인 바이오제약 기업 머크는 미국 식품의약국(FDA)에 생후 6개월 이상 소아에서 클로스트리디움(구 클로스트리디움) 및 디피실 관련 설사증(CDAD) 치료제인 '디피시드(Dificid)' 경구 현탁액(NDA) 및 정제(sNDA) 로 경구용 현탁액 'DIFICID(피닥소마이신)'의 신약승인신청(NDA) 및 정제 'DIFICID'의 추가신약승인신청(sNDA)을 승인했다고 발표했습니다. 또한, 소아 항생제에 대한 수요 증가는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2021년 유엔아동기금(UNICEF)은 54개국에서 1세 미만 영유아에게 3,160만 건의 항생제 치료를 제공했습니다.
본 보고서의 주요 특징
- 세계의 소아용 항생제 시장에 대해 조사 분석했으며, 2021년을 기준 연도로 하여 예측 기간(2022-2030년)의 시장 규모와 연평균 성장률(CAGR)에 대해 조사 분석하여 전해드립니다.
- 또한, 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
- 세계 소아 항생제 시장의 주요 기업 프로파일을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등의 매개 변수를 기반으로 정리하여 수록하고 있습니다.
- '세계 소아 항생제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 소아 항생제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 소아용 항생제 시장 : 감염증별(2026-2033년)
제5장 세계의 소아용 항생제 시장 : 투여 경로별(2026-2033년)
제6장 세계의 소아용 항생제 시장 : 유통 채널별(2026-2033년)
제7장 세계의 소아용 항생제 시장 : 지역별(2026-2033년)
제8장 경쟁 구도
제9장 섹션
KSMPediatric Antibiotics Market is estimated to be valued at USD 6.8 Bn in 2026 and is expected to reach USD 9.2 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 6.8 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.10% | 2033 Value Projection: | USD 9.2 Bn |
Antibiotics are used to treat or prevent some types of bacterial infection. Antibiotics work by killing bacteria or preventing them from reproducing and spreading. Antibiotics are the most commonly prescribed drugs in children and have the potential to save the lives of patients with severe bacterial infections such as Non-Specific Upper Respiratory Tract Infections, Urinary Tract Infections etc. They are taken orally and come in the form of tablets, liquid suspension, and capsules. Antibiotics are also administered through the intravenous route. Antibiotics are available in the form of ointments, creams, lotions, etc. for topical administration.
Market Dynamics
Key players operating in the global pediatric antibiotics market are focusing on adoption of growth strategies such as product approval, which is expected to drive market growth during the forecast period. For instance, in January 2020, Merck a leading global biopharmaceutical company known as MSD outside of the U.S. and Canada, announced that the U.S. Food and Drug Administration (FDA) had approved a New Drug Application (NDA) for DIFICID (fidaxomicin) for oral suspension, and a supplemental New Drug Application (sNDA) for DIFICID tablets for the treatment of Clostridioides (formerly Clostridium) difficile-associated diarrhea (CDAD) in children aged six months and older. Moreover, increasing demand of pediatric antibiotics is expected to propel market growth over the forecast period. For instance, in 2021, United Nations International Children's Emergency Fund (UNICEF) delivered 31.6 million antibiotic treatments to children under one year of age in 54 countries.
Key features of the study
- This report provides in-depth analysis of the global pediatric antibiotics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global pediatric antibiotics market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Johnson & Johnson, Astellas Pharma, Inc, Pfizer Inc., Novartis AG, Bayer AG, Bristol-Myers Squibb Company, Abbott., DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy's Laboratories Ltd, Teva Pharmaceuticals USA, Inc., Aurobindo Pharma USA, GlaxoSmithKline Plc., Hikma Pharmaceuticals PLC, Cipla Inc., Glenmark Pharmaceuticals, and Torrent Pharmaceuticals Ltd. Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global pediatric antibiotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pediatric antibiotics market.
Market Segmentation
- By Infection
- Acute Sinusitis
- Acute Otitis Media
- Non-Specific Upper Respiratory Tract Infections
- Urinary Tract Infections and Others
- By Route Of Administration
- Oral
- Topical
- Intravenous
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
- By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Johnson & Johnson
- Astellas Pharma, Inc
- Pfizer Inc.
- Novartis AG
- Bayer AG
- Bristol-Myers Squibb Company
- DAIICHI SANKYO COMPANY, LIMITED
- Reddy's Laboratories Ltd
- Teva Pharmaceuticals USA, Inc.
- Aurobindo Pharma USA
- GlaxoSmithKline Plc.
- Hikma Pharmaceuticals PLC
- Cipla Inc.
- Glenmark Pharmaceuticals
- Torrent Pharmaceuticals Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Infection
- Market Snapshot, By Route Of Administration
- Market Snapshot, By Distribution Channels
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Regulatory Scenario
- Market Trends
- Key Developments
- Epidemiology
- PEST Analysis
- Collaboration and Acquisition
- Porters Analysis
- Treatment Algorithm
4. Global Pediatric Antibiotics Market, By Infection, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Acute Sinusitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Acute Otitis Media
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Non-Specific Upper Respiratory Tract Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Urinary Tract Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
5. Global Pediatric Antibiotics Market, By Route of Administration, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
6. Global Pediatric Antibiotics Market, By Distribution Channel, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- E-Commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
7. Global Pediatric Antibiotics Market, By Region, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Infection, 2026 -2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Infection, 2026 -2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Infection, 2026 -2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (USD Bn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Infection, 2026 -2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Infection, 2026 -2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Infection, 2026 -2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Astellas Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.,
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- DAIICHI SANKYO COMPANY, LIMITED
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Reddy's Laboratories Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceuticals USA, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Aurobindo Pharma USA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline Plc.,
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hikma Pharmaceuticals PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Torrent Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson
9. Section
- Research Methodology
- About us
